Pharmafile Logo

Women’s health – managing the menopause

PME spoke to Marci English, Vice President and Head of BioPharma Development, Astellas, about the importance of new treatments for menopause symptoms, the unmet need and the company’s commitment to midlife women’s health
- PMLiVE

PME: More than half of women aged 40 to 64 years of age experience vasomotor symptoms (VMS). How are they characterised?
Marci English (ME): VMS, also known as hot flashes and/or night sweats, are common symptoms of menopause that can cause sudden and intense sensations of heat in the face, neck and chest, and last from one to five minutes. They can vary in severity, ranging from mild to moderate to severe, and may be accompanied by sweating, reddening of the skin, chills and rapid heartbeat. A hot flash is defined as mild when there is a sensation of heat without sweating, moderate when there is the sensation of heat with sweating, but the woman can continue her current activity, and severe when the sensation of intense heat with sweating interferes with the continuation of an activity.

PME: The prevalence of moderate-to-severe VMS in postmenopausal women in Europe has been reported as being at 40%. What are some of the most significant challenges women face in their everyday lives?
ME: VMS can have a disruptive impact on women’s daily activities and overall quality of life and are the most common symptom of menopause for which people seek treatment. VMS can last for ten years or more with the average duration being 7.4 years. During this time, the average woman may experience 33 hot flushes and night sweats per week (according to a UK study), though this can vary depending on the person, and can impact many everyday aspects of a woman’s life, including sleep, the ability to focus and personal relationships.

PME: Beyond its physical manifestations, what impact can menopause have on mental well-being?
ME: Menopause can impact women’s mental health, with 76% experiencing irritability, 29% experiencing depression and 14% experiencing anxiety. Forgetfulness, poor concentration, loss of self-esteem and/or confidence, low mood and sadness also can occur.

Read the article in full here.

Marci English is Vice President and Head of BioPharma Development at Astellas
18th April 2024
Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links